Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [41] The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
    Dong, Heng
    Zhang, Zhengguo
    Ni, Mengjie
    Xu, Xiaoyun
    Luo, Yifeng
    Wang, Yaru
    Zhang, Haiyun
    Chen, Jianxiang
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (10) : 1239 - 1256
  • [42] Hepatocellular carcinoma: tumor heterogeneity and recurrence after preoperative locoregional therapy
    Santo, Joana Espirito
    Ladeirinha, Ana
    Alarcao, Ana
    Strelet, Eugeniu
    Reis, Marco
    Santos, Rui
    Carvalho, Lina
    MEDICAL ONCOLOGY, 2023, 40 (12)
  • [43] Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma (Vol 13, 1197698, 2023)
    Xie, Shuqi
    Wang, Mengchao
    Zeng, Chuanxiu
    Ou, Yan
    Zhao, Lu
    Wang, Dong
    Chen, Liwei
    Kong, Fanming
    Yi, Dan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] Locoregional and systemic therapy for hepatocellular carcinoma
    Gbolahan, Olumide B.
    Schacht, Michael A.
    Beckley, Eric W.
    LaRoche, Thomas P.
    O'Neil, Bert H.
    Pyko, Maximilian
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (02) : 215 - 228
  • [45] Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis
    Yang, Sha
    Lin, Huapeng
    Song, Jianning
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [46] Nonrigid Registration for Evaluating Locoregional Therapy of Hepatocellular Carcinoma
    Dong, Chunhua
    Seki, Toshihito
    Inoguchi, Ryosuke
    Lin, Chen-Lun
    Han, Xianhua
    Chen, Yen-Wei
    PROCEEDINGS OF THE 2013 6TH INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND INFORMATICS (BMEI 2013), VOLS 1 AND 2, 2013, : 811 - 816
  • [47] CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma
    Xiang, Hua
    Long, Lin
    Yao, Yuanhui
    Fang, Zhiyong
    Zhang, Zhiming
    Zhang, Yongjin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2019, 18
  • [48] Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
    Chami, Perla
    Jarnagin, William
    Abou-Alfa, Ghassan K.
    Harding, James
    Kim, Neal
    Lin, Haibo
    El Homsi, Maria
    Crane, Christopher
    Hajj, Carla
    CANCERS, 2023, 15 (06)
  • [49] MRI assessment of hepatocellular carcinoma after locoregional therapy
    Hussein, Rasha S.
    Tantawy, Wahid
    Abbas, Yasser A.
    INSIGHTS INTO IMAGING, 2019, 10 (01)
  • [50] Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
    Yoo, Eun Jin
    Shin, Hye Sun
    Kim, Seung Up
    Joo, Dong Jin
    Park, Jun Yong
    Choi, Gi Hong
    Kim, Do Young
    Ahn, Sang Hoon
    Seong, Jinsil
    Koh, Myung Joo
    Han, Kwang-Hyub
    Chon, Chae Yoon
    ONCOTARGETS AND THERAPY, 2013, 6 : 755 - 759